New and promising DR-TB drugs are grabbing headlines but not reaching patients.

International organizations Partners In Health (PIH), Médecins Sans Frontières (MSF), Interactive Research and Development (IRD) and their financial partner UNITAID will start in April the endTB project, a partnership aimed at radically changing the management of multidrug-resistant tuberculosis (MDR-TB).

As countries mark World Tuberculosis Day on March 24, WHO is calling for “global solidarity and action” to support a new 20-year strategy, which aims to end the global tuberculosis epidemic.

STAND trial will take place in approximately 50 study sites in Africa, Asia, Caribbean, Eastern Europe, and Latin America; Results published in The Lancet show PaMZ’s promise to dramatically shorten and simplify therapy for patients with drug-resistant TB; Regimen could improve treatment for those with drug-sensitive TB and those with HIV co-infection.

Phase 3 STAND trial launched to advance PaMZ through final stage of testing.

It is essential to conduct studies that can determine whether this mutation is present in neighboring countries such as South Africa or Mozambique: “If we’re facing wide distribution of this strain in Southern Africa or elsewhere, it is imperative that the rapid molecular tests we currently use, as well as those under development, be adapted to detect a wider range of mutations”.

Tuberculosis cases down by 6% in 2013 – pace too slow to reach elimination this century. Rates of MDR-TB remain at very high levels, making the European Region the most affected area of the entire world.

А letter from 89 organizations urges action to accelerate access to new and repurposed drugs to treat drug-resistant tuberculosis.

Special open access supplement to The Journal of Infectious Diseases on TB diagnostics.

Community groups sent public comments in support of the addition of rifapentine, delamanid, bedaquiline and linezolid to the WHO Model List of Essential Medicines.